» Articles » PMID: 25249503

Physiological Effects and Therapeutic Potential of Proinsulin C-peptide

Overview
Date 2014 Sep 25
PMID 25249503
Citations 39
Authors
Affiliations
Soon will be listed here.
Abstract

Connecting Peptide, or C-peptide, is a product of the insulin prohormone, and is released with and in amounts equimolar to those of insulin. While it was once thought that C-peptide was biologically inert and had little biological significance beyond its role in the proper folding of insulin, it is now known that C-peptide binds specifically to the cell membranes of a variety of tissues and initiates specific intracellular signaling cascades that are pertussis toxin sensitive. Although it is now clear that C-peptide is a biologically active molecule, controversy still remains as to the physiological significance of the peptide. Interestingly, C-peptide appears to reverse the deleterious effects of high glucose in some tissues, including the kidney, the peripheral nerves, and the vasculature. C-peptide is thus a potential therapeutic agent for the treatment of diabetes-associated long-term complications. This review addresses the possible physiologically relevant roles of C-peptide in both normal and disease states and discusses the effects of the peptide on sensory nerve, renal, and vascular function. Furthermore, we highlight the intracellular effects of the peptide and present novel strategies for the determination of the C-peptide receptor(s). Finally, a hypothesis is offered concerning the relationship between C-peptide and the development of microvascular complications of diabetes.

Citing Articles

Impact of Platelet-to-HDL-Cholesterol Ratio on Long-Term Mortality in Coronary Artery Disease Patients with or Without Type 2 Diabetes: Insights from a Chinese Multicenter Cohort.

Wu W, Jia C, Xu X, He Y, Xie Y, Zhou Y J Inflamm Res. 2024; 17:2731-2744.

PMID: 38737110 PMC: 11086646. DOI: 10.2147/JIR.S458950.


The metabolome as a diagnostic for maximal aerobic capacity during exercise in type 1 diabetes.

Taylor G, Smith K, Scragg J, McDonald T, Shaw J, West D Diabetologia. 2024; 67(7):1413-1428.

PMID: 38662134 PMC: 11153288. DOI: 10.1007/s00125-024-06153-0.


Future clinical prospects of C-peptide testing in the early diagnosis of gestational diabetes.

Milionis C, Ilias I, Lekkou A, Venaki E, Koukkou E World J Exp Med. 2024; 14(1):89320.

PMID: 38590302 PMC: 10999065. DOI: 10.5493/wjem.v14.i1.89320.


The Correlation Between C-Peptide and Severity of Peripheral Atherosclerosis in Type 2 Diabetes Mellitus.

Wahab M, Alhabibi A, Sakr A, Zakaria M, Saleh O, Ahmad I Diabetes Metab Syndr Obes. 2023; 16:2617-2625.

PMID: 37663202 PMC: 10474844. DOI: 10.2147/DMSO.S426956.


Prediagnostic markers of insulin resistance and prostate cancer risk and death: A pooled study.

Jochems S, Fritz J, Haggstrom C, Stattin P, Stocks T Cancer Med. 2023; 12(12):13732-13744.

PMID: 37102250 PMC: 10315749. DOI: 10.1002/cam4.6004.


References
1.
Steiner D, Cunningham D, SPIGELMAN L, Aten B . Insulin biosynthesis: evidence for a precursor. Science. 1967; 157(3789):697-700. DOI: 10.1126/science.157.3789.697. View

2.
Zhang W, Kamiya H, Ekberg K, Wahren J, Sima A . C-peptide improves neuropathy in type 1 diabetic BB/Wor-rats. Diabetes Metab Res Rev. 2006; 23(1):63-70. DOI: 10.1002/dmrr.672. View

3.
Melles E, Jornvall H, Tryggvason S, Gemzell Danielsson K, Ekberg K, Tryggvason K . Degradation of proinsulin C-peptide in kidney and placenta extracts by a specific endoprotease activity. Cell Mol Life Sci. 2004; 61(23):2979-82. DOI: 10.1007/s00018-004-4313-7. View

4.
Remuzzi G, Macia M, Ruggenenti P . Prevention and treatment of diabetic renal disease in type 2 diabetes: the BENEDICT study. J Am Soc Nephrol. 2006; 17(4 Suppl 2):S90-7. DOI: 10.1681/ASN.2005121324. View

5.
Gier B, Krippeit-Drews P, Sheiko T, Aguilar-Bryan L, Bryan J, Dufer M . Suppression of KATP channel activity protects murine pancreatic beta cells against oxidative stress. J Clin Invest. 2009; 119(11):3246-56. PMC: 2769178. DOI: 10.1172/JCI38817. View